An intriguing association between congestive heart failure and diabetes mellitus

Chinese Medical Journal

Volumn 123, Issue 6, 2010, Pages 643-645

  Shen, Wei Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

ADRENERGIC SYSTEM; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; EDEMA; EDITORIAL; HEART LEFT VENTRICLE FAILURE; HIGH MOBILITY GROUP BOX DOMAIN; HUMAN; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; RECEPTORS, IMMUNOLOGIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 77949835412     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.06.001     Document Type: Editorial

References (32)

1. Shen WF. Screening for coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. Chin Med J 2007; 120: 1859-1861.
2. Shen WF. Improving long-term outcomes of coronary intervention in patients with diabetes. Chin Med J 2009; 122: 605-607.
3. Zhang Q, Shen J, Zhang RY, Qiu JP, Lu JD, Zhang Y, et al. Outcomes after primary coronary intervention with drug-eluting stent implantation in diabetic patients with acute ST myocardial infarction. Chin Med J 2007; 120: 1862-1867.
4. Liang CS, Delehanty JD. Increasing post-myocardial infarction heart failure incidence in elderly patients. A call for action. J Am Coll Cardiol 2009; 53: 21-23.
5. Cohen-Solar A, Beauvais F, Loqeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail 2008; 14: 615-625.
6. Dai SM, Zhang S, Chen KP, Hua W, Wang FZ, Chen X, et al. Prognostic factors affecting the all-cause death and sudden cardiac death rates of post myocardial infarction patients with low left ventricular ejection fraction. Chin Med J 2009; 122: 802-806.
7. Choy CK, Rodgers JE, Nappi JM, Haines ST. Type 2 diabetes mellitus and heart failure. Pharmacotherapy 2008; 28: 170-192.
8. Shi C, Wang LJ, Hu DF, Li JP, Zhu TQ, Shan Y, et al. Prevalence, clinical characteristics and outcome in patients with chronic heart failure and diabetes. Chin Med J 2010; 123: 646-650.
9. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24: 1614-1619.
10. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodenheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
11. Fonarow GC. An approach to heart failure and diabetes mellitus. Am J Cardiol 2005; 96 Suppl: 47E-52E.
12. Zheng ZL, Mcissner A, Hausmann B, Alexander H, Simon R. Prognostic value of Doppler transmitral filling patterns in patients with chronic heart failure. Chin Med J 2004; 117: 176-182.
13. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008; 29: 12-20.
14. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009; 54: 422-428.
15. Goode KM, John J, Rigby AS, Kilpatrick ES, Atkin SL, Braqadeesh T, et al. Elevated glycated hemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart 2009; 95: 917-923.
16. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
17. Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, et al. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J 2007; 28: 2879-2885.
18. Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 2007; 13: 199-206.
19. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11: 191-195.
20. Hunt SA, Abranham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in Collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
21. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al. Efficacy of ACE inhibitors and beta blockers in the management of left ventricular systolic dysfunction according to race, sex, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-1538.
22. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
23. Holman RR, Paul SK, Bethel A, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576.
24. Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart failure (OPTIMIZE-HF). Am Heart J 2007; 154: 277. e1-e8.
25. Eurich DT, Majumdar SR, McClister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-2351.
26. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515.
27. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atovastatin in type 2 diabetes in the Collaborative Atovastatin Diabetes Study (CARDS): Multicenter randomized placebo-controlled trial. Lancet 2004; 364: 658-696.
28. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001; 38: 421-428.
29. Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, et al. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions. Results from a real-world multicenter registry. J Am Coll Cardiol 2008; 117: 923-930.
30. BARI investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 2007; 49: 1600-1606.
31. Cook SA, Varela-Carver A, Mongillo M, Kleiner C, Kran MT, Strickland N, et al. Abnormal myocardial insulin signaling in type 2 diabetes and left ventricular dysfunction. Eur Heart J 2010; 31: 100-111.
32. Boden WE, Taggart DP. Diabetes with coronary disease - a moving target aimed evolving therapies ? N Engl J Med 2009; 360: 2570-2572.